Business Wire

GIGABYTE

Share
GIGABYTE to Introduce Leading-Edge AI Solutions and Computers at COMPUTEX 2023, Unveiling “Future of COMPUTING”

GIGABYTE, a leading innovator of computer hardware and server solutions, announces its unprecedented exhibits at COMPUTEX 2023. Resonating its theme “Future of COMPUTING”, GIGABYTE is unveiling its all-around technical achievements, including industry-leading AI/HPC servers, green computing solutions, gaming and creator products, industrial PC, AI smart securities, and autonomous vehicle technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005112/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

GIGABYTE to Introduce Leading-Edge AI Solutions and Computers at COMPUTEX 2023, Unveiling “Future of COMPUTING” (Graphic: Business Wire)

Besides product exhibits, GIGABYTE will hold a four-day Tech Talk with speakers from AMD, Ampere, Intel, and NVIDIA, sharing insights about how the future of computing is reshaping the technology landscapes. The exhibition will be held from May 30th to June 2nd on the 1st floor, Taipei Nangang Exhibition Center, Hall 1.

Take the Lead in the AI Era with GIGABYTE’s Trailblazing GPU/HPC Servers

The emergence of ChatGPT and various generative AI applications are making huge waves of industry evolution, driving all-time demand for AI computing servers. At COMPUTEX, GIGABYTE and its subsidiary, Giga Computing, are unveiling a cutting-edge lineup of GPU-accelerated servers and HPC servers. These solutions are aimed at accelerating exascale data analysis, deep learning, machine learning, inferencing, large language models (LLM), and generative AI training tasks, unlocking the unparalleled breakthroughs of AI development.

The latest lineup of GPU/HPC server solutions is powered by the latest CPU platform, GPU accelerator cards, and AI deep learning and inference technologies from leading tech partners. With GIGABYTE’s exclusive density-optimized server design and cooling technology, AI computing servers can achieve superior performance and energy efficiency, allowing enterprises and institutes to become the front-runner in AI competition.

Strike the Goals of Data Center Sustainability with GIGABYTE’s Immersion Cooling Solutions

The advent of AI technology has raised concerns about surging electricity consumption and carbon emissions, leading to the growing demand for data center cooling solutions designed to save power, boost computing performance, and reduce total cost of ownership (TCO). For the first time, GIGABYTE is showcasing three models of immersion cooling tanks and corresponding server series, demonstrating its widely acclaimed green computing solutions at COMPUTEX.

GIGABYTE's immersion cooling solutions have established admirable standards in energy efficiency and cost-effectiveness; therefore, they have been adopted by global semiconductor giants, telecommunication services, and European top research centers. GIGABYTE’s self-developed total solutions include the immersion cooling tanks, server configuration designs, and automatic monitoring and adjustment mechanisms, allowing enterprises and institutions to embrace sustainability and achieve innovation breakthroughs.

Explore the Gaming and Creator Computers with Lightspeed Overlocking

In addition to enterprise solutions, GIGABYTE is exhibiting a comprehensive computer portfolio, including the 2023 Red Dot Design Award-winning AORUS and AERO motherboards, graphics cards, and laptops, as well as STEALTH 500 computer assembly kit that won CES Innovation Award, SSD and large-size 4K monitors. All of these demonstrate GIGABYTE’s technical prowess and exceptional aesthetics. Tech enthusiasts at the booth will be thrilled to explore how GIGABYTE’s computers are pushing the performance beyond the limits and offering immersive experiences.

Grasp the Insights of Industry-Leading AI Trends at GIGABYTE Tech Talk

During the four-day COMPUTEX exhibition, GIGABYTE’s booth is holding Tech Talk sessions with diverse topics. Speakers from technology giants will share first-hand insights of AI advancements and green computing technologies, delivering various perspectives of “Future of COMPUTING” to the audiences.

Visit GIGABYTE’s COMPUTEX event page.
Subscribe to GIGABYTE newsletter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005112/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release

Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release

SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f

Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release

Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr

IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release

Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye